144 related articles for article (PubMed ID: 38503969)
1. Utility of LEF1 to differentiate desmoid fibromatosis from its histologic mimics.
Jobbagy S; Lozano-Calderon S; Mullen JT; Nielsen GP; Hung YP; Chebib I
Virchows Arch; 2024 May; 484(5):807-813. PubMed ID: 38503969
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the usefulness of nuclear beta-catenin in the diagnosis of desmoid-type fibromatosis among commonly used anti-beta-catenin antibodies.
Yamada Y; Hirata M; Sakamoto A; Noguchi T; Ito K; Nishida Y; Matsuda S; Haga H
Pathol Int; 2021 Jun; 71(6):392-399. PubMed ID: 33788979
[TBL] [Abstract][Full Text] [Related]
3. Comparison of β-Catenin and LEF1 Immunohistochemical Stains in Desmoid-type Fibromatosis and its Selected Mimickers, With Unexpected Finding of LEF1 Positivity in Scars.
Zou Y; Zhang Y; Church J; Liu X
Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):648-653. PubMed ID: 28027119
[TBL] [Abstract][Full Text] [Related]
4. Nuclear TFE3 expression is a diagnostic marker for Desmoid-type fibromatosis.
Zhou L; Xu H; Zhou J; Dong L; Zhang P; Yang X; Wang C
Diagn Pathol; 2019 May; 14(1):34. PubMed ID: 31043173
[TBL] [Abstract][Full Text] [Related]
5. Differential diagnostic considerations of desmoid-type fibromatosis.
Goldstein JA; Cates JM
Adv Anat Pathol; 2015 Jul; 22(4):260-6. PubMed ID: 26050263
[TBL] [Abstract][Full Text] [Related]
6. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool.
Amary MF; Pauwels P; Meulemans E; Roemen GM; Islam L; Idowu B; Bousdras K; Diss TC; O'Donnell P; Flanagan AM
Am J Surg Pathol; 2007 Sep; 31(9):1299-309. PubMed ID: 17721184
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature.
Carlson JW; Fletcher CD
Histopathology; 2007 Oct; 51(4):509-14. PubMed ID: 17711447
[TBL] [Abstract][Full Text] [Related]
8. Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions.
Bhattacharya B; Dilworth HP; Iacobuzio-Donahue C; Ricci F; Weber K; Furlong MA; Fisher C; Montgomery E
Am J Surg Pathol; 2005 May; 29(5):653-9. PubMed ID: 15832090
[TBL] [Abstract][Full Text] [Related]
9. Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor.
Verschoor AJ; Cleton-Jansen AM; Wijers-Koster P; Coffin CM; Lazar AJ; Nout RA; Rubin BP; Gelderblom H; Bovée JV
Am J Surg Pathol; 2015 Dec; 39(12):1701-7. PubMed ID: 26414222
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Utility of LEF1 Immunohistochemistry in Differentiating Deep Penetrating Nevi From Histologic Mimics.
Raghavan SS; Saleem A; Wang JY; Rieger KE; Brown RA; Novoa RA
Am J Surg Pathol; 2020 Oct; 44(10):1413-1418. PubMed ID: 32520758
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.
Sakai T; Nishida Y; Hamada S; Koike H; Ikuta K; Ota T; Ishiguro N
Diagn Pathol; 2017 Aug; 12(1):66. PubMed ID: 28851389
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic Utility of LEF1 Immunostain in Cytology Specimens of Solid Pseudopapillary Neoplasm of Pancreas].
Farzaneh T; Nowroozizadeh B; Han M; Lee W
Acta Cytol; 2021; 65(3):250-256. PubMed ID: 33887729
[TBL] [Abstract][Full Text] [Related]
13. Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas.
Tandon B; Peterson L; Gao J; Nelson B; Ma S; Rosen S; Chen YH
Mod Pathol; 2011 Nov; 24(11):1433-43. PubMed ID: 21685909
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of lymphoid enhancer-binding factor 1 (LEF1) in solid-pseudopapillary neoplasms of the pancreas.
Singhi AD; Lilo M; Hruban RH; Cressman KL; Fuhrer K; Seethala RR
Mod Pathol; 2014 Oct; 27(10):1355-63. PubMed ID: 24658583
[TBL] [Abstract][Full Text] [Related]
15. Is immunohistochemical staining for β-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional study.
Koike H; Nishida Y; Kohno K; Shimoyama Y; Motoi T; Hamada S; Kawai A; Ogose A; Ozaki T; Kunisada T; Matsumoto Y; Matsunobu T; Ae K; Gokita T; Sakai T; Shimizu K; Ishiguro N
Hum Pathol; 2019 Feb; 84():155-163. PubMed ID: 30292627
[TBL] [Abstract][Full Text] [Related]
16. Nuclear GSK-3β segregation in desmoid-type fibromatosis.
Meneghello C; Ousghir B; Rastrelli M; Anesi L; Sommariva A; Montesco MC; Rossi CR; Hladnik U; Segat D
Histopathology; 2013 Jun; 62(7):1098-108. PubMed ID: 23614534
[TBL] [Abstract][Full Text] [Related]
17. CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics.
Le Guellec S; Soubeyran I; Rochaix P; Filleron T; Neuville A; Hostein I; Coindre JM
Mod Pathol; 2012 Dec; 25(12):1551-8. PubMed ID: 22766794
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics.
Hung YP; Fletcher CDM; Hornick JL
Histopathology; 2018 Oct; 73(4):634-644. PubMed ID: 29863809
[TBL] [Abstract][Full Text] [Related]
19. TGF-β and CTGF are Mitogenic Output Mediators of Wnt/β-Catenin Signaling in Desmoid Fibromatosis.
Varghese S; Braggio DA; Gillespie J; Toland AE; Pollock R; Mayerson J; Scharschmidt T; Iwenofu OH
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):559-565. PubMed ID: 26894649
[TBL] [Abstract][Full Text] [Related]
20. Gardner fibroma: a clinicopathologic and immunohistochemical analysis of 45 patients with 57 fibromas.
Coffin CM; Hornick JL; Zhou H; Fletcher CD
Am J Surg Pathol; 2007 Mar; 31(3):410-6. PubMed ID: 17325483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
